Clinical Report: Myopia: Assessing Artificial Intelligence
Overview
Artificial intelligence (AI) is transforming myopia management by enhancing diagnostics, treatment planning, and patient education. However, the integration of AI also poses significant risks, including misinformation and confirmation bias, which can adversely affect clinical decision-making.
Background
The rise of myopia as a public health concern necessitates innovative management strategies. AI technologies offer the potential for improved patient care through personalized treatment approaches. However, the risks associated with AI, such as misinformation and deepfake technologies, must be carefully managed to ensure evidence-based practices are upheld.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
- AI can enhance speed, consistency, and scalability in myopia management.
- Misinformation from AI can lead to harmful clinical decisions, such as delaying evidence-based treatments.
- Deepfake technologies pose risks by fabricating clinical data and images, undermining evidence-based medicine.
- AI can amplify confirmation bias, leading to treatment plans based on perception rather than scientific evidence.
- Critical thinking and improved editorial standards are essential to combat the risks associated with AI in healthcare.
Clinical Implications
Healthcare professionals must remain vigilant against the risks of misinformation and confirmation bias when utilizing AI in myopia management. It is crucial to integrate AI as a supportive tool that enhances clinical judgment rather than replacing it.
Conclusion
While AI presents exciting opportunities for advancing myopia care, its integration must be approached with caution to mitigate risks and ensure that patient care remains evidence-based.
References
- Maria Liu, OD, PHD, MPH, MBA, FAAO, Contact Lens Spectrum, 2025 -- AI in Practice
- Maria Liu, OD, PHD, MPH, MBA, FAAO, Optometric Management, 2025 -- Myopia: Beware ‘Google MD’ 2.0
- IMI-Interventions for Controlling Myopia Onset and Progression 2025
- contact lens spectrum — AI in Practice
- conexiant — AI Supports Glaucoma Surgical Planning
- IMI-Interventions for Controlling Myopia Onset and Progression 2025
- Low-dose atropine for myopia progression in children: a 2017-2024 systematic review and meta-analysis of randomized placebo-controlled trials - PubMed
- Frontiers | Artificial intelligence in pathologic myopia: a review of clinical research studies
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.